Protecting brain cells in protein-clumping diseases by boosting mitochondria and natural protein helpers

Slowing proteotoxic neurodegeneration by boosting mitochondrial bioenergetics and recruiting a novel class of chaperones

NIH-funded research Miami VA Health Care System · NIH-11212791

This project aims to protect brain cells in people with protein-misfolding diseases like Huntington's and Parkinson's by improving mitochondrial energy and recruiting natural protein 'chaperone' enzymes.

Quick facts

Grant typeNIH-funded research
Study typeNIH-funded research
Funding institutionMiami VA Health Care System NIH-funded
Lab location1 site (Miami, United States)
Project IDNIH-11212791 on NIH RePORTER

What this research studies

Researchers are studying how boosting the cell's energy factories (mitochondria) and turning on everyday enzymes to act as protein "helpers" can prevent harmful protein clumps in neurons. They use yeast, fruit fly, and mouse models to find which enzymes in the NAD+ salvage pathway can act as chaperones and protect cells under proteotoxic stress. The team tests whether increasing mitochondrial biogenesis or overexpressing enzymes such as NMNAT/NMA1, NADS/Qns1, NaPTRase/Npt1 and NDase/Pnc1 reduces protein damage and improves neuron survival. Results could point to new treatment strategies that restore energy balance and protein folding in neurodegenerative disorders.

Who could benefit from this research

Good fit: People with Huntington's disease, Parkinson's disease, or other neurodegenerative disorders caused by toxic protein aggregation would be the most relevant candidates for future therapies arising from this work.

Not a fit: Patients with conditions that are not driven by protein misfolding or those with very advanced neuronal loss may be unlikely to benefit directly from these approaches.

Why it matters

Potential benefit: If successful, this work could lead to therapies that reduce toxic protein buildup and slow cognitive and movement decline in disorders like Huntington's and Parkinson's.

How similar studies have performed: Related work in yeast, fly and some mouse models has shown that boosting mitochondrial function and NMNAT-family enzymes can protect against proteotoxicity, but translation to humans remains unproven.

Where this research is happening

Miami, United States

Researchers

About this research

  1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
  2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
  3. For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Last reviewed 2026-06-13 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.